Lee Scott Golden Sells 1,340 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 1,340 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $76.95, for a total transaction of $103,113.00. Following the completion of the sale, the executive vice president owned 93,936 shares of the company’s stock, valued at $7,228,375.20. This trade represents a 1.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lee Scott Golden also recently made the following trade(s):

• On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $49,742.16.

PTC Therapeutics Price Performance

PTC Therapeutics stock traded down $0.39 during mid-day trading on Thursday, reaching $76.85. The company had a trading volume of 1,625,361 shares, compared to its average volume of 1,684,365. The stock’s 50-day simple moving average is $76.26 and its 200-day simple moving average is $62.43. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The company has a market capitalization of $6.17 billion, a P/E ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. During the same quarter in the prior year, the firm posted ($1.39) EPS. The company’s revenue was up 7.2% compared to the same quarter last year. On average, equities analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Institutional Investors Weigh In On PTC Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in shares of PTC Therapeutics by 4.8% during the third quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after buying an additional 224,481 shares during the period. State Street Corp grew its stake in PTC Therapeutics by 22.1% in the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock worth $146,347,000 after acquiring an additional 541,558 shares during the period. Geode Capital Management LLC raised its holdings in PTC Therapeutics by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,593 shares of the biopharmaceutical company’s stock valued at $94,497,000 after acquiring an additional 60,707 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in PTC Therapeutics in the 3rd quarter valued at $97,252,000. Finally, Palo Alto Investors LP lifted its stake in shares of PTC Therapeutics by 112.2% during the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after purchasing an additional 456,144 shares during the period.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on PTCT shares. Barclays lifted their price target on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Morgan Stanley reaffirmed an “overweight” rating and issued a $90.00 price target on shares of PTC Therapeutics in a report on Thursday. Royal Bank Of Canada lowered shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and increased their price target for the company from $82.00 to $91.00 in a research report on Monday, December 1st. TD Cowen lifted their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen raised PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $77.27.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.